348 related articles for article (PubMed ID: 18785508)
21. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA
Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
[TBL] [Abstract][Full Text] [Related]
22. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of lower dose rituximab therapy for idiopathic thrombocytopenic purpura.].
Sui T; Xue F; Zhao HF; Ge J; Zhou H; Zhang L; Bai J; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2010 Mar; 31(3):161-3. PubMed ID: 20510104
[TBL] [Abstract][Full Text] [Related]
24. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
Al-Ahmad M; Al-Rasheed M; Al-Muhani A
J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793
[TBL] [Abstract][Full Text] [Related]
25. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
26. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
27. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
29. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
Kuwana M; Iki S; Urabe A
Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
32. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP).
Najaoui A; Bakchoul T; Stoy J; Bein G; Rummel MJ; Santoso S; Sachs UJ
Eur J Haematol; 2012 Feb; 88(2):167-74. PubMed ID: 21985182
[TBL] [Abstract][Full Text] [Related]
33. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
35. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children.
Dai WJ; Zhang RR; Yang XC; Yuan YF
Eur Rev Med Pharmacol Sci; 2015 Jul; 19(13):2379-83. PubMed ID: 26214772
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G
Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
[TBL] [Abstract][Full Text] [Related]
38. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R
Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C
Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
[TBL] [Abstract][Full Text] [Related]
40. [Identification of human platelet specific functional antibody and its fragments].
Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]